Positive Data From Astra, Hutchison China Cancer Drug Trial
March 31 2019 - 11:30AM
Dow Jones News
By Carlo Martuscelli
Interim results from a phase 1 clinical trial, titled Patton,
show that Savolitinib combined with an already-approved medicine,
Tagrisso, yielded positive results.
Savolitinib is an investigational therapy under development by
AstraZeneca PLC (AZN.LN) in partnership with Hutchison China
MediTech Ltd. (HCM.LN).
Data presented at the 2019 annual American Association for
Cancer Research meeting showed that lung cancer patients are
responding to the combined treatment.
The study looked at the effect of Savolitinib and Tagrisso in
patients with non-small cell lung cancer with a mutation in the
EGFR gene.
The objective response rate of the drug combination--a measure
of how many patients see a reduction in tumor size--ranged from
between 28% and 52%, based on what therapies they had previously
undergone.
Dr. Lecia Sequist, who presented the results, said the findings
show the benefit of adding a MET inhibitor--the class of drug to
which Savolitinib belongs--to already established therapies like
Tagrisso in patients whose cancer has acquired drug resistance.
However, she cautioned that this is still early-stage data and
the findings need to be confirmed in larger trials.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
March 31, 2019 11:15 ET (15:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024